HTB

CROI 2017 (Retrovirus)

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Impressive HIV pipeline at CROI 2017

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

New HIV diagnoses in children in UK and Ireland continue to decline

World Health Organisation paediatric dosing tool

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Immune-based therapy canakinumab reduces inflammatory markers in HIV positive people on ART

Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity

Increased risk of IRIS with integrase inhibitors reported in two studies

Breakthrough for treating XDR-TB and ameliorating TB-IRIS

PrEP in pregnancy does not increase poor birth outcomes

HIV cure research and basic science: capsules from CROI 2017

24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study

NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

No increase in adverse birth outcomes with maternal TDF/FTC in US study

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

No evidence of accelerated brain ageing in HIV positive people on effective ART

Acute infection with wild-type HIV on PrEP with good drug levels

Fit for purpose: antiretroviral treatment optimisation (Feb 2017)

Seattle-lite: pre-conference workshops – watch online